Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 147-154

  Zhou, Yan ^a   Gou, Lan Tu ^b   Guo, Zhi Hui ^a   Liu, Hai Rong ^a   Wang, Jiang Man ^b   Zhou, Shu Xian ^a   Yang, Jin Liang ^b   Li, Xiao An ^a  

^a FIRST AFFILIATED HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Bispecific antibody; Breast cancer; Cluster of differentiation 3; HER2; Immunotherapy

Indexed keywords

BISPECIFIC ANTIBODY; CLUSTER OF DIFFERENTIATION; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CD3 ANTIGEN; ERBB2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER INHIBITION; CHO CELL LINE; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; BREAST NEOPLASMS; CRICETULUS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HAMSTER; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PRIMARY CELL CULTURE; TUMOR ASSOCIATED LEUKOCYTE;

CRICETULUS GRISEUS;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; BREAST NEOPLASMS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; PRIMARY CELL CULTURE; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84926637585     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3441     Document Type: Article

References (29)

1. El Saghir NS and Anderson BO: Breast cancer early detection and resources: where in the world do we start? Breast 21: 423-425, 2012.
2. Yu ZG, Jia CX, Liu LY, et al: The prevalence and correlates of breast cancer among women in Eastern China. PLoS One 7: e37784, 2012.
3. Oliva S, Cioffi G, Frattini S, et al: Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? Oncologist 17: 917-924, 2012.
4. de Hoon JP, Veeck J, Vriens BE, Calon TG, van Engeland M and Tjan-Heijnen VC: Taxane resistance in breast cancer: a closed HER2 circuit? Biochim Biophys Acta 1825: 197-206, 2012.
5. Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H and Lekka I: Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. J BUON 17: 277-283, 2012.
6. Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379: 633-640, 2012.
7. Boulaamane L, Boutayeb S and Errihani H: Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study. BMC Res Notes 5: 162, 2012.
8. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
9. Blok EJ, Kuppen PJ, van Leeuwen JE and Sier CF: Cytoplasmic overexpression of HER2: a key factor in colorectal cancer. Clin Med Insights Oncol 7: 41-51, 2013.
10. Conti M, Hsieh M, Park JY and Su YQ: Role of the epidermal growth factor network in ovarian follicles. Mol Endocrinol 20: 715-723, 2006.
11. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43, 2007.
12. Larbouret C, Robert B, Navarro-Teulon I, et al: In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 13: 3356-3362, 2007.
13. Burstein HJ: The distinctive nature of HER2-positive breast cancers. N Engl J Med 353: 1652-1654, 2005.
14. Bayoudh L, Afrit M, Daldoul O, et al: Trastuzumab (herceptin) for the medical treatment of breast cancer. Tunis Med 90: 6-12, 2012.
15. Wang CX, Koay DC, Edwards A, Lu Z, Mor G, Ocal IT and Digiovanna MP: In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer. Breast Cancer Res Treat 92: 251-263, 2005.
16. Rugo H, Brammer M, Zhang F and Lalla D: Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer 10: 288-293, 2010.
17. Shepard HM, Jin P, Slamon DJ, et al: Herceptin. Handb Exp Pharmacol 181: 183-219, 2008.
18. Wolf E, Hofmeister R, Kufer P, et al: BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discovery Today 10: 1237-1244, 2005.
19. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36: 458-67, 2010.
20. Bargou R, Leo E, Zugmaier G, et al: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974-977, 2008.
21. Yamamoto K, Trad A, Baumgart A, et al: A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 445: 135-144, 2012.
22. Wu G, Fan X, Wu H, et al: Bioscreening of phage display antibody library and expression of a humanized single-chain variable fragment antibody against human connective tissue growth factor (CTGF/CCN2). Biotechnol Appl Biochem 56: 95-102, 2010
23. Petsch S, Gires O, Rüttinger D, Denzel S, Lippold S, Baeuerle PA and Wolf A: Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs 3: 31-37, 2011.
24. Jäger M, Schoberth A, Ruf P, et al: Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res 72: 24-32, 2012.
25. Reusch U, Sundaram M, Davol PA, et al: Anti-CD3 anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 12: 183-190, 2006.
26. Kasuya K, Shimazu M, Suzuki M, Itoi T, Aoki T and Tsuchida A: Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer. Int J Mol Med 25: 209-215, 2010.
27. Stebbings R, Findlay L, Edwards C, et al: 'Cytokine storm' in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179: 3325-3331, 2007.
28. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
29. Finn RS and Slamon DJ: Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif 21: 223-233, 2003.